Grau-Bejar Juan Francisco, Garcia-Duran Carmen, Garcia-Illescas David, Mirallas Oriol, Oaknin Ana
Gynaecologic Cancer Programme Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
Head of Gynaecological Cancer Program, Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), P. Vall d'Hebron 119-129, Barcelona 08035, Spain.
Ther Adv Med Oncol. 2023 Mar 28;15:17588359231163836. doi: 10.1177/17588359231163836. eCollection 2023.
Cervical cancer still represents a major public health problem, being the fourth most common cancer in incidence and mortality in women worldwide. These figures are unacceptable since cervical cancer, an human papillomavirus-related malignancy, is a largely preventable disease by means of well-established screening and vaccination programs. Patients with recurrent, persistent, or metastatic disease unsuitable for curative therapeutic approaches represent a dismal prognosis population. Until recently, these patients were only candidates for cisplatin-based chemotherapy plus bevacizumab. However, the introduction of immune checkpoint inhibitors has revolutionized the treatment landscape of this disease achieving historical overall survival improvements in both the post-platinum and frontline settings. Interestingly, the clinical development of immunotherapy in cervical cancer is currently advancing to earlier stages of the disease, as the locally advanced setting, whose standard of care has not changed in the last decades with still modest outcomes. As more innovative immunotherapy approaches are in clinical early development in advanced cervical cancer, promising efficacy data are emerging that may shape the future of this disease. This review summarizes the main treatment advances carried out in the field of immunotherapy throughout the past years.
宫颈癌仍然是一个重大的公共卫生问题，是全球女性中发病率和死亡率第四高的常见癌症。这些数据是不可接受的，因为宫颈癌作为一种与人乳头瘤病毒相关的恶性肿瘤，通过完善的筛查和疫苗接种计划在很大程度上是可预防的疾病。患有复发性、持续性或转移性疾病且不适合根治性治疗方法的患者预后不佳。直到最近，这些患者还只是基于顺铂的化疗联合贝伐单抗的候选者。然而，免疫检查点抑制剂的引入彻底改变了这种疾病的治疗格局，在铂类治疗后和一线治疗中均实现了历史性的总生存期改善。有趣的是，宫颈癌免疫疗法的临床开发目前正在推进到疾病的早期阶段，如局部晚期阶段，其护理标准在过去几十年中没有改变，结果仍然一般。随着更多创新的免疫疗法在晚期宫颈癌的临床早期开发中出现，有前景的疗效数据正在涌现，这可能会塑造这种疾病的未来。这篇综述总结了过去几年免疫疗法领域取得的主要治疗进展。
